udy that beautifully illustrates the value of advanced lipid profiling, direct LDL determination and the value of postprandial measurement of remnant lipoproteins," said James Ehrlich, M.D., Atherotech's Chief Medical Officer and an expert in coronary calcification imaging. And beyond research, the accurate identification of lipid profiles and subclasses can have a major impact on proper individualized therapy and improved cardiac risk assessment, which may also include imaging tests and endothelial function testing, as in this research."
The improved lipid profile of mutation carriers included: significantly lower levels of non-HDL, very low density lipoprotein (VLDL), VLDL3 (the most-dense VLDL subfraction), intermediate density lipoprotein (IDL), real LDL, and remnant lipoprotein cholesterol. Higher (cardioprotective) levels of both HDL2 and HDL3 cholesterol were also reported along with apparent cardioprotection as measured by decreased prevalence of coronary artery calcification.
The VAP Test, which is covered by most insurance carriers and Medicare, provides physicians with direct measurement of LDL, HDL and all relevant cholesterol subclasses. These important but often overlooked subclasses include non-HDL, particle number as determined by accurate apoB, and emerging risk factors such as Lp(a), low-density lipoprotein remnants and small dense LDL.
VAP technology has been used in more than 100 clinical trials and will continue to play an important role in clinical practice and as a valuable analytical research tool. The VAP Test is available nationwide.
About Atherotech, Inc.
Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP technology, which directly measures the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with up
'/>"/>
SOURCE Atherotech, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects of Combination Therapy2.
Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 20083.
VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured4.
VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment5.
Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients6.
New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)7.
Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management8.
VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured9.
Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy10.
Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination11.
Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels